Back to top
more

Gilead Sciences (GILD)

(Delayed Data from NSDQ)

$64.70 USD

64.70
7,412,684

+0.85 (1.33%)

Updated Jun 7, 2024 04:00 PM ET

After-Market: $64.62 -0.08 (-0.12%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (85 out of 248)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Here's Why You Should Add Ligand (LGND) Stock to Your Portfolio

Ligand's (LGND) proprietary platforms enable it to form partnerships with several leading drug companies, providing it with funds through milestone and royalty payments.

Gilead Sciences (GILD) Gains But Lags Market: What You Should Know

In the latest trading session, Gilead Sciences (GILD) closed at $83.24, marking a +0.33% move from the previous day.

Bristol Myers' (BMY) Breyanzi Gets Positive CHMP Opinion

Bristol Myers (BMY) receives a positive CHMP opinion for CAR T cell therapy with Breyanzi for relapsed or refractory large B-cell lymphoma after one prior treatment.

Should iShares Select Dividend ETF (DVY) Be on Your Investing Radar?

Style Box ETF report for DVY

IGM Biosciences, Inc. (IGMS) Reports Q4 Loss, Misses Revenue Estimates

IGM Biosciences, Inc. (IGMS) delivered earnings and revenue surprises of 22.22% and 0.80%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Arcellx, Inc. (ACLX) Reports Q4 Loss, Misses Revenue Estimates

Arcellx, Inc. (ACLX) delivered earnings and revenue surprises of -7.04% and 100%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Gilead Sciences (GILD) Gains As Market Dips: What You Should Know

Gilead Sciences (GILD) closed at $80.99 in the latest trading session, marking a +1.77% move from the prior day.

Should You Invest in the VanEck Biotech ETF (BBH)?

Sector ETF report for BBH

Biotech Stock Roundup: ALT Obesity Data, GILD Exercises Option, INCY Drug Approval

Incyte's (INCY) skin cancer drug approval and Altimmune's obesity data are the key highlights from the biotech sector during the past week.

Is iShares Select Dividend ETF (DVY) a Strong ETF Right Now?

Smart Beta ETF report for DVY

Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?

Smart Beta ETF report for IBB

Gilead Sciences (GILD) Dips More Than Broader Markets: What You Should Know

Gilead Sciences (GILD) closed at $77.81 in the latest trading session, marking a -1.68% move from the prior day.

Gilead (GILD) Announces OS Data on Yescarta From ZUMA-7 Study

Gileads Yescarta shows statistically significant improvement in overall survival for initial treatment of R/R LBCL patients versus historical standard of care in curative setting.

Should SPDR Russell 1000 Yield Focus ETF (ONEY) Be on Your Investing Radar?

Style Box ETF report for ONEY

Gilead (GILD) Exercises Option to License Nurix's Candidate

Gilead (GILD) exercises an option under its collaboration agreement with Nurix to license the latter???s investigational targeted protein degrader molecule NX 0479.

Nurix's (NRIX) Stock Up Due to License Option Exercise by Gilead

Nurix Therapeutics (NRIX) to earn an option fee of $20 million as partner Gilead exercised its option to exclusively license Nurix's investigational targeted protein degrader molecule NX 0479.

Gilead Sciences (GILD) Gains But Lags Market: What You Should Know

Gilead Sciences (GILD) closed at $79.85 in the latest trading session, marking a +0.25% move from the prior day.

Gilead (GILD) Gains 34% in 12 Months: Will the Trend Sustain?

Gilead (GILD) gains 34% in the past 12 months as its HIV business and rapidly growing oncology business maintain momentum despite volatility.

Gilead Sciences (GILD) Stock Moves -0.15%: What You Should Know

In the latest trading session, Gilead Sciences (GILD) closed at $79.65, marking a -0.15% move from the previous day.

Is SPDR Russell 1000 Yield Focus ETF (ONEY) a Strong ETF Right Now?

Smart Beta ETF report for ONEY

Should You Invest in the iShares Biotechnology ETF (IBB)?

Sector ETF report for IBB

Should IQ Chaikin U.S. Large Cap ETF (CLRG) Be on Your Investing Radar?

Style Box ETF report for CLRG

Gilead Sciences (GILD) Stock Moves -1.55%: What You Should Know

In the latest trading session, Gilead Sciences (GILD) closed at $78.96, marking a -1.55% move from the previous day.

Is Franklin U.S. Low Volatility High Dividend Index ETF (LVHD) a Strong ETF Right Now?

Smart Beta ETF report for LVHD